Ad Code: 57787

Similar survival outcomes of a real-world study of a first-line treatment regimen were demonstrated in the phase 3 IMpower133 trial. The study, IFCT 1905-CLINATEZO, assessed the safety and effectiveness of chemotherapy plus...

For patients with NSCLC ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival (OS) compared with single- agent chemotherapy, according to a study published...

In patients with NSCLC, the use of antibiotics around immune checkpoint inhibitor (ICI) initiation was linked with reduced overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), according to a...